

Johnson & Johnson (Janssen) COVID-19 Vaccine Update April 27, 2021

On April 23rd, the FDA and CDC lifted the recommended pause on the use of the Johnson & Johnson (J&J) COVID-19 vaccine following a thorough safety review. The Western States Scientific Safety Review Workgroup also supported this recommendation. Sacramento County Public Health agrees that the vaccine is safe and providers should resume use of the J&J COVID-19 vaccine to prevent the continued spread of the disease, severe disease, and deaths from COVID-19.

CDC Recommends Use of Johnson & Johnson's Janssen COVID-19 Vaccine Resume:


- CDC and the U.S. Food and Drug Administration (FDA) recommend use of Johnson & Johnson's Janssen (J&J/Janssen) COVID-19 Vaccine resume in the United States, after a temporary pause.
- Reports of adverse events following the use of J&J/Janssen vaccine suggest an increased risk of a rare adverse event called thrombosis with thrombocytopenia syndrome (TTS). Nearly all reports of this serious condition, which involves blood clots with low platelets, have been in adult women younger than 50 years old.
- A review of all available data at this time shows that the J&J/Janssen COVID-19 Vaccine's known and potential benefits outweigh its known and potential risks.
- However, women younger than 50 years old should be aware of the rare but increased risk of this adverse event and that there are other COVID-19 vaccine options available for which this risk has not been seen.
- CDC and FDA will continue to monitor the safety of all COVID-19 vaccines.
- **Remind patients to seek medical care right away** if they develop [any symptoms after receiving](#) the J&J/Janssen COVID-19 Vaccine.

Health care providers should remind patients to register for V-safe (<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html>) and also report any adverse events to the Vaccine Adverse Event Reporting System (<https://vaers.hhs.gov/reportevent.html>).

Resources

1. FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review: <https://www.cdc.gov/media/releases/2021/fda-cdc-lift-vaccine-use.html>
2. CDPH Issues Statement on Western States' Approval to Resume use of Johnson & Johnson Vaccine: <https://www.cdph.ca.gov/Programs/OPA/Pages/NR21-136.aspx#>
3. CDPH Fact Sheet: Johnson & Johnson COVID-19 Vaccine Benefits and Risks: https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/COVID-19/InI_factsheet.pdf

Sincerely,



Olivia Kasirye, MD, MS
Public Health Officer